Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 4, 2021
- Accepted in final form July 15, 2021
- First Published September 8, 2021.
Author Disclosures
- Martin S. Weber, MD*,
Evobrutinib Phase II steering committee
NONE
He received travel funding and/or speaker honoraria from Biogen-Idec, Merck Serono, Novartis, Roche, TEVA, Bayer and Genzyme.
Academic Editor for PLoS One
NONE
NONE
NONE
NONE
NONE
NONE
NONE
He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.
He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jacqueline A. Nicholas, MD, MPH* and
(1)Alexion (2)Biogen (3)Novartis (4)Genentech (5) Bristol Myers Squib (6)EMD Serono (7) GW Pharmaceuticals
NONE
(1) Novartis (2) Alexion (3) EMD Serono (4) Bristol Myers Squibb (5) Genentech
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Alexion (3) EMD Serono (4) Bristol Myers Squibb (5) Genentech
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael R. Yeaman, PhD
NONE
NONE
NONE
(1) Associate Editor, Frontiers in Immunology 2020-present (2) Associate Editor, Frontiers in Microbiology 2020-present
(1) Vaccines targeting drug-resistant pathogens (2) Immunotherapies targeting drug-resistant pathogens (3) Novel anti-infective biological therapeutics (4) Novel anti-infective small molecules (5) Novel biologicals regulating programmed cell death
NONE
NONE
(2) Advisor, Guthy-Jackson Charitable Foundation (1) Consultant, Genentech-Roche (3) Advisor, Alexion (1) Advisor, Horizon
NONE
NONE
NONE
NONE
(1) United States Department of Defense (2) United States National Institutes of Health
NONE
NONE
Metacin, Inc.
NONE
NONE
NONE
NONE
NONE
- From the Institute of Neuropathology (M.S.W.), University Medical Center; Department of Neurology (M.S.W.), University Medical Center, Göttingen, Germany; OhioHealth Multiple Sclerosis Center (J.A.N.), Riverside Methodist Hospital, Columbus, OH; David Geffen School of Medicine (M.R.Y.), University of California, Los Angeles (UCLA); Divisions of Molecular Medicine and Infectious Diseases (M.R.Y.), Harbor-UCLA Medical Center; and Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (M.R.Y.), Torrance, CA.
- Correspondence
Dr. Weber martin.weber{at}med.uni-goettingen.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- Glossary
- BTKis in the Treatment of MS
- BTK Signaling
- Effect of BTKis on Antimicrobial Host Defense in General
- COVID-19 Pathogenesis and Risk of Severe Infection
- BTKi Mechanisms of Action and COVID-19 Pathology
- Evidence of the Effect of BTKis on COVID-19 Risk
- Emerging Insights Regarding the Effect of BTKis on COVID-19 Vaccination
- Summary and Concluding Remarks
- Study Funding
- Disclosure
- Appendix Authors
- Footnotes
- References
- Figures & Data
- Info & Disclosures
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
COVID-19 and MS disease-modifying therapiesJoseph R. Berger, Rachel Brandstadter, Amit Bar-Or et al.Neurology: Neuroimmunology & Neuroinflammation, May 15, 2020 -
Article
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 AntibodiesAn Observational StudyKévin Bigaut, Laurent Kremer, Thibaut Fabacher et al.Neurology: Neuroimmunology & Neuroinflammation, July 28, 2021 -
Editor's Corner
N2 year in reviewJosep Dalmau, Marinos C. Dalakas, Dennis L. Kolson et al.Neurology: Neuroimmunology & Neuroinflammation, December 18, 2020 -
Commentary
COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying TherapyAndrew Wolf, Enrique Alvarez et al.Neurology: Clinical Practice, April 14, 2021